Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — FY2018 Earnings Presentation
31 slides from Hyphens Pharma International's earnings presentation, Mar 6, 2019
Slide 1: General Announcement: Hyphens Results Briefing 4Q2018 / FY2018
REPL::General Announcement::Hyphens Results Briefing 4Q2018 / FY... Page 1 of 1 REPL::GENERAL ANNOUNCEMENT::HYPHENS RESULTS BRIEFING 4Q2018 / FY2018 Issuer & Securities Issuer/ Manager HYPHENS PHARMA INTERNATIONAL LIMITED Securities HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5 Stapled Security N
Slide 2: Results Briefing 4Q2018 / FY2018
Hyphens Pharma International Limited Results Briefing 4Q2018 / FY2018 HYPHENS PHARMA INTL LTD (SGX: 1J5)
Slide 3: Disclaimer
DISCLAIMER This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation n
Slide 4: Company Snapshot
COMPANY SNAPSHOT ON LISTED ON 18 MAY THE 2018 SGX-CATALIST 3 CORE 2018 REVENUE 5 COUNTRIES BUSINESSES S$121 MILLION 450 EMPLOYEES 14 of our products are sold every minute!
Slide 5: Share Statistics
IPO Price SHARE STATISTICS S$0.26 With Market Capitalisation of S$78m SGX Closing Price Stock Code on 4 March 2019 Cornerstone Investors 1J5 S$0.19 @ IPO Market Bloomberg Capitalisation Stock Code S$57m Nikko Asset Management HYP:SP (P/E excl IPO Qilin Asset Management exp approx. 9x) Maxi-Harvest G
Slide 6: Business Evolution Timeline
BUSINESS EVOLUTION TIMELINE 2018 Medical Hypermart and Digital Specialty Pharma Principals Proprietary Brands 2001 Entry into Specialty Pharma thru Hyphens Pharma 2017 2004 2007 Patent filed in UK for next generation of Ceradan® products 1998 2011 2016 Acquired • Launched • Acquired Pan-Malayan Cera
Slide 7: Our Business Segments
OUR BUSINESS SEGMENTS Specialty Pharma Principals Proprietary Brands Medical Hypermart and Digital
Slide 8: Specialty Pharma Principals
SPECIALTY PHARMA PRINCIPALS What We Do 1. Handle specialised products, under exclusive agreements with our principals from Europe and the US. 2. Register and hold product licenses with local authorities. 3. Promote products through medical representatives to specialists and GPs.
Slide 9: Our Regional Footprint
OUR REGIONAL FOOTPRINT Our Staff Strength 1882 23 29 148 622 Direct presence 1. As at 31 Dec 2018 2. Based on representative offices and distributors
Slide 10: Contrast Media Products
CONTRAST MEDIA PRODUCTS GUERBET – XENETIX® DOTAREM® LIPIODOL® Our products are used for: • X-Rays • CT Scans • MRI Participation in Scientific Congresses years of 25 working relationship 2018 Revenue Contribution: 13.7% Booth Presence Symposiums
Slide 11: ENT (Ear, Nose, Throat) & Allergy
ENT (EAR, NOSE, THROAT) & ALLERGY
Slide 12: Other Specialty Pharma Products
OTHER SPECIALTY PHARMA PRODUCTS Interventional Cardiology Gastroenterology (Biosensors Coronary Stents) Obstetrics & Gynaecology Otorhinolaryngology Rheumatology Ophthalmology Neuroscience & Psychiatry Family Medicine
Slide 13: Proprietary Brands
PROPRIETARY BRANDS What We Do 1. Direct ownership of the products under various brand names and market them to the world. 2. Constantly engaged in product research & development. 3. Contract manufacture these products, bearing our trademarks.
Slide 14: Brands We Own
BRANDS WE OWN Ccéan am Ceradan’ Quality You Can Trust DERMA FORMULA Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group i") Hyphens
Slide 15: Atopic Dermatitis Range
ATOPIC DERMATITIS RANGE Gentle Non-Soap Wash Maintenance Therapy * Triple Protective Action Specially-Formulated Against Diaper Rash Mosquito Repellent For AD Menthol Gel to Calm & Soothe Itchy Skin Ceramide-Dominant Therapeutic Moisturiser *IQVIA 2018 Q3 Survey on Top-of-Mind Awareness on 31 Privat
Slide 16: Clinically Tested Products
CLINICALLY TESTED PRODUCTS • Clinical collaborations with KK Women’s and Children’s Hospital and National Skin Centre on Ceradan® regimen • Publication in Journal of Dermatology and Therapy Case Study in Indonesia – Ceradan® Diaper Cream
Slide 17: Atopic Dermatitis Treatment Market Size
ATOPIC DERMATITIS TREATMENT MARKET SIZE (USD$) Market Report from Future Market Insights, 2017 Global: $5.8B Global: $24B ASEAN $596M ASEAN $210M
Slide 18: TDF Derma Formula
TDF® DERMA FORMULA HOME CARE OILY & ACNE DRY & SENSITIVE HYPER- PIGMENTATION AGE DEFENSE CHEMICAL PEEL
Slide 19: A Well-Regarded Brand by Consumers
A WELL-REGARDED BRAND BY CONSUMERS Brand that I can trust# Good value for money# WINNER WINNER Guardian Health & Watsons Beauty Awards HWB Award since 2008 since 2007 * WINNER Unity Popular WINNER Superbrands Status SINGAPORE’S NO. 1OMEGA-3 Choice Award since 2004 since 2008 # 2018 Nielsen Surve
Slide 20: Nutritional Supplements
NUTRITIONAL SUPPLEMENTS Clinical Series is a professional range of health supplement products to meet the clinical nutrition needs of patients
Slide 21: We Market Our Brands In
WE MARKET OUR BRANDS IN Bangladesh Hong Kong Oman Myanmar Philippines Cambodia Vietnam Malaysia Brunei Singapore Indonesia
Slide 22: Medical Hypermart and Digital
MEDICAL HYPERMART AND DIGITAL What We Do 1. Wholesaler of pharmaceutical products and medical supplies. 2. Cater largely to private clinics and pharmacies. 3. > 3,000 customers and > 4,000 items in our inventory. 4. Have B2B e-commerce platform that facilitates 24/7 ordering. 5. Only in Singapore at
Slide 23: Medical Hypermart and Digital
MEDICAL HYPERMART AND DIGITAL 1st pharmaceutical wholesaler in Singapore to establish an online platform and capture new Over 1,500 digital opportunities members on Medical Hypermart! MORE THAN YEARS HERITAGE BRAND
Slide 24: Financial Snapshot as at Dec 2018
FINANCIAL SNAPSHOT AS AT 31 DEC 2018 FY2018 S$7.5m S$22.4m cash inflow from cash and cash equivalent REVENUE operating activities S$120.9m Strong Cash 7.7% Generative Business PROFIT gearing ratio1 Low Gearing Ratio S$5.4m 1 Total Debt / Total Equity (after IPO expense of S$0.9m) 0.55c >30% dividend
Slide 25: Financial Review & Highlights (4Q2018)
FINANCIAL REVIEW & HIGHLIGHTS 4Q2018 vs 4Q2017 • Revenue for 4Q2018 by 12.8% to S$30.0 million (4Q2017: S$26.6 million) • Revenue was mainly due to an in sales in specialty pharma principals & proprietary brand segments - Higher demand for coronary stents and radiology products - Higher demand
Slide 26: Financial Review & Highlights (FY2018)
FINANCIAL REVIEW & HIGHLIGHTS FY2018 vs FY2017 • Revenue for FY2018 by 7.3% to S$120.9 million (FY2017: S$112.7 million) • Revenue was mainly due to an in sales of specialty pharma principals & proprietary brand segments - Higher demand for allergy, radiology and musculoskeletal products - Imp
Slide 27: Financial Highlights
FINANCIAL HIGHLIGHTS Revenue (S$’m) Profit After Tax (S$’m) 6.1 112.7 120.9 101 5.2 5.4 78.3 5.1 FY2015 FY2016 FY2017 FY2018 FY2015 FY2016 FY2017 FY2018
Slide 28: Revenue Segment Breakdown by Business & Geography
REVENUE SEGMENT BREAKDOWN BY BUSINESS & GEOGRAPHY FY18 Revenue Breakdown by FY18 Revenue Breakdown by Business (S$’m) Geography (S$’m) Medical Hypermart & Digital Others 6.7 (5.5%) 38.4 7.7 (6.4%) (31.7%) 53.9 69.4 (44.5%) (57.4%) 52.7 13.2 (43.6%) (10.9%) Proprietary Specialty Pharma Brands Princip
Slide 29: Future Growth
FUTURE GROWTH • New product launches - Products with patented and patent pending technologies to grow the skin health business - Continue to enhance product offerings through licencing and research collaborations - Launching new specialty pharma products in regional markets • Establishing a broader
Slide 30: Product Pipeline
PRODUCT PIPELINE Atopic Dermatitis Pigmentation Acne Development Pending Pending 2019 in-Progress Registration Commercialisation Ceradan Advanced TDF® Fairence T-Complex HYP1101 HYP1102 HYP1302 HYP1304 HYP1306
Slide 31: Hyphens Pharma International Limited contact details
Hyphens Pharma International Limited (SGX: 1J5) 16 Tai Seng Street, Level 4, Singapore 534138 www.hyphens.com.sg
Hyphens Pharma International — FY2018 Earnings Presentation on 6ix